I-Corps: Natural Compounds for Wound Healing

I-Corps：用于伤口愈合的天然化合物

• 批准号: 1811949
• 负责人: Ehsan Jabbarzadeh
• 金额: $ 5万
• 依托单位: University of South Carolina at Columbia
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2018-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1811949&HistoricalAwards=false
• 关键词: Corps; Natural; Compounds; Wound; Healing

The broader impact/commercial potential of this I-Corps project is providing affordable and effective method to treat chronic wounds based on the use of two natural compounds. Chronic wounds affect millions of people in US and account for a significant fraction of overall health care costs. Nevertheless, the regeneration of skin remains a huge challenge due to its multilayered structure and the presence of different cell types organized within the extracellular matrix. This complexity necessitates the use of multi-functional drugs with antioxidant, anti-inflammatory, anti-microbial, pro-angiogenesis and pro-healing properties. The potential advantages of the proposed treatment strategy over conventional approaches include reduced cost, decreased side-effects, lower risk of infection, and increased patient compliance.This I-Corps project core technology is a chronic wound healing product composed of two phenolic compounds isolated from a botanical source to yield an active source of anti-inflammatory, pro-angiogenic and pro-regeneration activities. Chronic wound healing is a complex physiological process controlled by a well-orchestrated cascade of interdependent biochemical and cellular events. The proposed innovation harnesses the multi-targeting ability of natural compounds to modulate the crosstalk between inflammation, epithelialization and vascular formation in chronic wounds. The team will potentially develop a minimum viable product based on a proprietary formulation of phenolic natural compounds to accelerate fibroblast and keratinocytes migration, enhance blood vessel formation, and modulate macrophage response. The scope of this project is not necessarily confined to the field of wound repair. Unraveling the cellular and molecular modes of action that regulate immunomodulatory signaling cascades is an important step in drug discovery with a wide array of potential applications.

该I-Corps项目的更广泛的影响/商业潜力是根据使用两种天然化合物提供负担得起有效的方法来治疗慢性伤口。慢性伤口会影响美国数以百万计的人，并占整体医疗保健费用的很大一部分。然而，由于其多层结构以及在细胞外基质中组织的不同细胞类型的存在，皮肤的再生仍然是一个巨大的挑战。这种复杂性需要使用具有抗氧化剂，抗炎，抗微生物，促血管生成和亲链性特性的多功能药物。拟议的治疗策略比常规方法的潜在优势包括成本降低，副作用降低，感染的风险降低以及患者依从性的增加。这项I-Corps项目核心技术是一种慢性伤口愈合产物，由从植物学源分离出的两种酚类化合物，从植物学源中分离出来，以产生抗炎，促炎性，促疾病，促进性，促进性，pro-angi-angientic和pro-regregeneration。慢性伤口愈合是一个复杂的生理过程，该过程由良好的相互依存生化和细胞事件的级联反应控制。提出的创新可以利用自然化合物在慢性伤口中调节炎症，上皮化和血管形成之间的串扰的多目标能力。该团队将根据酚类天然化合物的专有配方来开发最低可行的产品，以加速成纤维细胞和角质细胞迁移，增强血管形成并调节巨噬细胞反应。该项目的范围不一定仅限于伤口修复领域。阐明调节免疫调节信号级联的细胞和分子作用模式是药物发现的重要一步，并具有广泛的潜在应用。